CoChat
Sign Up
Cited by 110Brain Metastases and TreatmentLung Cancer Treatments and MutationsGlioma Diagnosis and Treatment

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: A systematic review and meta-analysis

Soon, Yu Yang, Leong, Cheng Nang, Koh, Wee Yao, Tham, Ivan Weng Keong·2015·Radiotherapy and Oncology
DOI 10.1016/j.radonc.2014.12.011
Open this paper in CoChat — free account

Abstract

Background and purpose EGFR TKIs alone have demonstrated activity against intracranial disease in EGFR mutant non-small cell lung cancer (NSCLC). This study aimed to determine if upfront cranial radiotherapy improves intracranial disease control and survival outcomes in EGFR mutant NSCLC with brain metastases relative to TKIs alone.Materials and methods We searched MEDLINE and various conference proceedings from 2008 to July 2014 for eligible studies where patients received upfront cranial radiotherapy or TKIs alone. Outcomes of interest were overall intracranial disease response rate (ORR), four-month intracranial disease progression-free survival (PFS), two-year overall survival (OS) and neurological adverse events (AE). We used random effects models to pool outcomes across studies and compared them using interaction tests.Results We found 12 non-comparative observational studies (n=363) with severe methodological limitations. Upfront cranial radiotherapy results in similar intracranial disease ORR (relative risk (RR) 0.93, 95% confidence interval (CI) 0.82-1.06; interaction p value (p)=0.53), improved four-month intracranial disease PFS (RR 1.06, 95% CI 1.00-1.12; p=0.03), improved two-year OS (RR 1.33, 95% CI 1.00-1.77; p=0.05) but caused more neurological AEs than TKIs alone.Conclusion There is evidence, albeit of low quality, that upfront cranial radiotherapy may improve intracranial disease control and survival outcomes compared with TKI alone.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.radonc.2014.12.011

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 42 references

Research works printed but not linked: 1

  1. Schuler, 2013, Efficacy of afatinib versus chemotherapy in treatment naïve patients with non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations with or without metastatic brain disease, J Thorac Oncol, 8, S299

Cited by

Sorted by citations

Items 101–110 of 110

Related

See all

Metadata

Authors
Soon, Y. Y., Leong, C. N., Koh, W. Y., & Tham, I. W. K.
Affiliations
National University of Singapore (SG)
Corresponding author
Soon, Yu Yang
ORCID
Venue
Radiotherapy and Oncology
Publisher
Elsevier BV
Published
2015-02
Volume
114
Issue
2
Pages
167-172
ISSN
0167-8140 (ISSN-L)
DOI
10.1016/j.radonc.2014.12.011
OpenAlex
W2021095467
Cited by
110
References
42
Citations by year
2025: 5 · 2024: 5 · 2023: 4 · 2022: 8 · 2021: 10 · 2020: 13 · 2019: 15 · 2018: 12 · 2017: 21 · 2016: 16 · 2015: 1
FWCI
2.95
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Radiotherapy and Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Brain Metastases and Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Keywords
EGFR tyrosine kinase inhibitors, cranial irradiation, EGFR mutation, non-small cell lung cancer, brain metastases, intracranial disease control, progression-free survival, overall survival, neurological adverse events, upfront radiotherapy
MeSH terms
Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Cranial Irradiation, Disease-Free Survival, Protein Kinase Inhibitors, Chemoradiotherapy, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review